PDO Thread Embedding Plus Binh Vi Tablets for Gastroesophageal Reflux Disease
A legfontosabb adatok
- Ki végzi
- University of Medicine and Pharmacy at Ho Chi Minh City
- Hol
- Vietnám1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Résztvevők
- 86 fő vett részt
- Kezdés
- 2026. márc. 20.
- Befejezés
- 2026. aug. 31.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- PDO Thread Embedding
- Esomeprazole 40 mg Oral Tablet
- Binh Vi Tablets
- A regiszteradat frissítve
- 2026. november 2.
Ki vehet részt
- Életkor
- 18 év – 60 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter összes feltétele (15)A regiszter feltételeinek elrejtése
Ki vehet részt
- Adults aged 18 to under 60 years presenting for examination and treatment at Ho Chi Minh City Traditional Medicine Hospital, regardless of sex or occupation
- Diagnosis of gastroesophageal reflux disease (GERD), defined as a GerdQ score of 8 or higher, with heartburn and/or regurgitation occurring at least 2 days per week, and an indication for standard-dose proton pump inhibitor (PPI) therapy according to the 2022 American College of Gastroenterology (ACG) and 2017 World Gastroenterology Organisation (WGO) guidelines
- Not currently receiving treatment for GERD
- Willingness to participate in the study and comply with the treatment regimen
Ki nem vehet részt
- Use of GERD medication within the specified washout periods before screening: PPIs within 14 days; histamine-2 receptor antagonists or prokinetics within 10 days; alginate-containing medications or antacids within 3 days; or herbal medicines for GERD at least 2 days per week
- Receipt of traditional medicine treatment for GERD within 14 days before screening
- History of esophageal and/or gastrointestinal surgery
- Any contraindication to acupoint thread embedding according to the 2013 Vietnamese Ministry of Health guidance, including an acute medical emergency, severe physical debilitation, reduced resistance, pregnancy, infection or skin disease at the acupoint sites, or allergy to absorbable sutures or acupuncture needles
- History of adverse reactions to proton pump inhibitors (PPIs), including reactions to formulation excipients
- Current use of anticoagulants or a coagulation disorder due to another medical condition
- Psychiatric illness or dementia
- Known inflammatory bowel disease; serious hepatic, renal, respiratory, or cardiovascular disease; serious comorbid conditions; rare hereditary disorders (including fructose intolerance, glucose-galactose malabsorption, or congenital sucrase-isomaltase deficiency); or a history of drug or alcohol abuse
- Current use of medications that may interfere with GERD treatment or assessment, including systemic glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs), calcium channel blockers, anticholinergics, bisphosphonates, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, tetracyclines, HIV protease inhibitors, rifampin, potassium supplements, iron, quinidine, zidovudine, alpha-adrenergic agents, beta-2 adrenergic agonists, benzodiazepines, barbiturates, dopamine, estrogens, progesterone, opioid analgesics, nitrates, prostaglandins, or theophylline
- Clinical alarm symptoms, including dysphagia, odynophagia, recurrent bronchial symptoms, aspiration pneumonia, dyspnea, recurrent or persistent cough, gastrointestinal bleeding, frequent nausea and/or vomiting, persistent pain, ongoing unintentional weight loss, lymphadenopathy, an epigastric mass, newly developed atypical symptoms between ages 45 and 55, or a family history of carcinoma of the esophagus or stomach
- Current participation in another interventional study
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this clinical trial is to learn if PDO thread embedding combined with Binh Vi tablets and Esomeprazole works better than Binh Vi tablets and Esomeprazole alone in treating gastroesophageal reflux disease (GERD) in adults.
A teljes eredeti leírásKevesebb
The main questions it aims to answer are:
* Does adding PDO thread embedding improve GERD symptoms more effectively? * Does the combined treatment improve participants' quality of life? * What adverse effects may occur during PDO thread embedding? Researchers will compare PDO thread embedding combined with Esomeprazole 40 mg and Binh Vi tablets to Esomeprazole 40 mg and Binh Vi tablets alone to evaluate symptom improvement, clinical response, quality of life, and safety.
Participants will:
* Be randomly assigned to receive either PDO thread embedding plus Esomeprazole 40 mg and Binh Vi tablets, or Esomeprazole 40 mg and Binh Vi tablets alone. * Receive treatment for 4 weeks. Participants in the PDO thread embedding group will receive 2 sessions, one every 2 weeks. * Visit the clinic for treatment and checkups. * Complete questionnaires about GERD symptoms and quality of life at the start of the study, at 2 weeks, and at 4 weeks.
A vizsgálat 2 csoportja
- PDO Thread Embedding + Esomeprazole 40 mg + Binh Vi TabletsA vizsgált kezelés
Participants receive PDO thread embedding twice over 4 weeks, once every 2 weeks, in addition to Esomeprazole 40 mg and Binh Vi tablets.
Kezelés: PDO Thread Embedding, Esomeprazole 40 mg Oral Tablet és Binh Vi Tablets
- Esomeprazole 40 mg + Binh Vi TabletsMár használt kezelés, összehasonlításként
Participants receive Esomeprazole 40 mg and Binh Vi tablets alone for 4 weeks, without PDO thread embedding.
Kezelés: Esomeprazole 40 mg Oral Tablet és Binh Vi Tablets
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Evaluation of the Effectiveness of PDO Thread Embedding Combined With Binh Vi Tablets in the Treatment of Gastroesophageal Reflux Disease (GERD)
- A regiszteradat frissítve
- 2026. november 2.